Reference
Henricks LM , et al. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. European Journal of Cancer 107: 60-67, 10 Dec 2018. Available from: URL: http://doi.org/10.1016/j.ejca.2018.11.010
Rights and permissions
About this article
Cite this article
Genotype-guided therapy reduces toxicity, saves costs. Reactions Weekly 1734, 1 (2019). https://doi.org/10.1007/s40278-019-56127-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-56127-y